PSMA and FDG PET scans before 177Lu-PSMA therapy
Part of Cancer, Kidney & urinary clinical trials.
This trial uses two types of PET scans (PSMA and FDG) to see how well a radioactive therapy called 177Lu-PSMA might work for men with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer has spread and is getting worse despite hormone therapy and chemotherapy.
- You have already been treated with a taxane chemotherapy (like docetaxel) and at least one anti-androgen drug (like enzalutamide).
- You are in good general health (able to be up and about most of the day).
- You are able to lie still for about 30 to 60 minutes for a PET scan.
- You are on a social health plan (like Medicare or equivalent).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
This trial tests if adding a radioactive drug called 177Lu-PSMA-617 to standard therapy helps men whose prostate cancer has spread and hasn't responded well to initial hormone therapy. It's for men whose PSA level is still detectable after 6-8 months of treatment.
This trial tests whether a special PET scan can predict how well a targeted radiation therapy (177Lu-PSMA-617) works for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to personalize treatment by checking the radiation dose before therapy starts.
This trial will test if a special PET scan (18F-DCFPyL) can help doctors plan your treatment with a radioactive medicine called 177Lu-vipivotide tetraxetan. You are eligible if you already qualify for that standard therapy and have had a prior PSMA PET scan showing at least one active cancer site.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
This trial studies whether a PSMA-targeted treatment using 177Lu can help men with prostate cancer that has spread and is growing despite hormone treatment. It may help if your scan shows high PSMA in the tumor and your blood counts and organ function are adequate.
Hear when a new Prostate Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.